MDGL

The MASH (Metabolic Dysfunction-Associated Steatohepatitis) market is rapidly expanding with over 180 companies developing 200+ pipeline therapies. Two drugs have been approved: REZDIFFRA (resmetirom) by Madrigal Pharmaceuticals and LIPAGLYN/BILYPSA (saroglitazar magnesium) by Zydus Lifesciences. The competitive landscape is intensifying with emerging mechanisms of action including FGF21 replacements, GLP-1 receptor agonists, and dual glucagon/GLP-1 agonists, with approximately 5+ drugs in late-stage development and 100+ in mid and early stages.

Novo Nordisk is expanding semaglutide into new indications like MASH and obesity-related conditions to diversify revenue beyond its core GLP-1 franchise. However, the company faces significant competitive pressure from Eli Lilly's broad incretin portfolio expansion and other competitors in the MASH market. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation with a Hold rating.